We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for selumetinib (AstraZeneca Pty Ltd)
Active ingredients
selumetinib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Hard capsule
Indication
Treatment of Neurofibromatosis Type 1
Therapeutic area
Oncology